Healthcare Technology Featured Article

September 23, 2011

BIOTRONIK Launches Renamic, Next-Gen Programmer for Implantable Cardiac Devices


Global manufacturer of cardiovascular medical devices BIOTRONIK announced the release of its Renamic product for the Japanese market. The announcement is in response to the dramatic growth of cardiac electrophysiology in the Japanese market, the company announced.

Renamic, one of the latest additions to BIOTRONIK's portfolio of external devices, will be used for programming, reprogramming and testing of implantable pacemakers, implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices in cardiac rhythm management (CRM), BIOTRONIK officials explained.

The product’s advantages include ease of use and versatile usage. Renamic's new user interface, which has been optimized with improved spacing and intuitive color-coding, is expected to increase the efficiency of patient follow-up. The product features a retractable and adjustable touch screen for optimized viewing and handling and can either be used with the stylus pen or with any other tool. The product also incorporates s tested and proven printer from a renowned printer manufacturer.

“The growth of cardiac electrophysiology in Japan is significant, and BIOTRONIK is committed to investing in support of this high potential market,” Managing Director of BIOTRONIK Dr .Werner Braun commented in a statement. “BIOTRONIK has put great effort into expediting the Japanese market access for Renamic, in order to ensure that our customers have the very latest in new programming technology.”

According to an estimate, the CRM market in Japan represents nearly 10 percent of the global market. BIOTRONIK has a long-standing history in Japan which started in the late 1970s.

In 2003, the company set up dedicated Japanese operations to establish direct connection with the Japanese market. The launch of the Renamic is important to the Japanese CRM market because this new generation programmer offers significant advantages with regards to helping optimize in-clinic patient care and cardiac implantable device function, officials at BIOTRONIK explained.

“We are pleased to be able to provide Renamic for cardiac clinical teams in Japan. Its easy handling will improve the user's experience as well as potentially save time and cost. Renamic starts a new era for convenient programming and follow-up of BIOTRONIK cardiac devices and improves daily clinic efficiency,” Managing Director of BIOTRONIK Japan Jeffrey Annis commented in a statement.

Last month, BIOTRONIK announced the European market approval of the Selectra left ventricular lead delivery system.


Madhubanti Rudra is a contributing editor for HealthTechZone. To read more of her articles, please visit her columnist page.

Edited by Carrie Schmelkin
Get stories like this delivered straight to your inbox. [Free eNews Subscription]




SHARE THIS ARTICLE



FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]